Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. May 7, 2013; 19(17): 2676-2682
Published online May 7, 2013. doi: 10.3748/wjg.v19.i17.2676
Published online May 7, 2013. doi: 10.3748/wjg.v19.i17.2676
Table 1 Baseline characteristics of all patients who received adalimumab for treatment of Crohn’s disease n (%)
Adalimumab | Combination | Total | |
n = 16 | n = 12 | n = 28 | |
Gender | |||
Male | 13 (81.3) | 9 (75.0) | 22 (78.6) |
Female | 3 (18.7) | 3 (25.0) | 6 (21.4) |
Age at presentation1 (yr) | 43.1 ± 11.8 | 31.4 ± 8.3a | 38.1 ± 11.8 |
Disease duration1 (yr) | 13.6 ± 11.5 | 9.3 ± 7.6 | 11.8 ± 10.1 |
Location of disease | |||
Isolated ileal | 2 (12.5) | 1 (8.3) | 3 (10.7) |
Isolated colonic | 4 (25.0) | 1 (8.3) | 5 (17.9) |
leocolonic | 10 (62.5) | 10 (83.3) | 20 (71.4) |
Previous resection | 10 (62.5) | 7 (58.3) | 17 (60.7) |
Perianal disease | 10 (62.5) | 6 (50) | 16 (57.1) |
Current smokers | 1 (6.3) | 1 (8.3) | 2 (7.1) |
Previous anti-infliximab treatment | 10 (62.5) | 7 (58.3) | 17 (60.7) |
Primary nonresponse | 0 (0.0) | 1 (8.3) | 1 (3.6) |
Secondary loss of response | 8 (50.0) | 6 (50.0) | 14 (50.0) |
Allergic reaction | 1 (6.3) | 0 (0.0) | 1 (3.6) |
Others | 1 (6.3) | 0 (0.0) | 1 (3.6) |
CDAI at initiation of adalimumab therapy1 | 195.4 ± 89.2 | 152.2 ± 65.8 | 177.8 ± 82.0 |
CDAI > 150 at initiation of adalimumab therapy, n | 9 | 7 | 16 |
CRP at initiation of adalimumab therapy1 | 0.72 ± 0.92 | 0.66 ± 0.73 | 0.70 ± 0.83 |
Table 2 Clinical efficacy of adalimumab therapy
- Citation: Ishida K, Inoue T, Fujiwara K, Sakanaka T, Narabayashi K, Nouda S, Okada T, Kakimoto K, Kuramoto T, Kawakami K, Abe Y, Takeuchi T, Murano M, Tokioka S, Umegaki E, Higuchi K. Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn’s disease patients. World J Gastroenterol 2013; 19(17): 2676-2682
- URL: https://www.wjgnet.com/1007-9327/full/v19/i17/2676.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i17.2676